CAR-T

Global First: Chinese CAR-T Therapy Simultaneously Cures Tumor and Lupus Erythematosus

China make advanced medical treatment affordable Wang Fang (pseudonym), residing in Yichang, Hubei, China, underwent a life-threatening ordeal. This patient in her forties had been suffering from systemic lupus erythematosus for over 20 years. What exacerbated her agony was the excruciating pain in her right leg since June 2019, which forced her into a wheelchair. Read More

December 26th,2023 CAR-T

Unveiling Hope: Chinese CAR-T Cell Therapy Illuminating New Paths in Liver Cancer Treatment!

2020, over 19.3 million people were diagnosed with cancer worldwide, leading to almost 10 million fatalities. In China alone, the number of new cancer patients reached a staggering 4.57 million, accounting for 23.7% globally. Liver cancer, among the most prevalent malignant tumors in China, witnessed 410,000 new cases and 380,000 deaths, making up 45.3% and Read More

December 25th,2023 CAR-T

The Emergence of Fifth Generation CAR-T: A Boon for Late-Stage Cancer Patients or a Major Breakthrough in Solid Tumor Treatment?

The fifth-generation CAR-T is designed as a universal type of CAR-T. Is this risk-free CAR-T capable of achieving significant breakthroughs in solid tumor treatment, or is it effectively reducing costs to enable scalable production and treatment? After nearly three decades of development, CAR (Chimeric Antigen Receptor) technology has undergone continuous innovation. Currently, CAR has evolved Read More

December 22nd,2023 CAR-T

CAR-T therapy for Lupus erythematosus

A type of cancer that affects your blood cells is called blood cancer. Myeloma, lymphoma, and leukemia are among the most prevalent forms of blood cancer. There are more varieties known as MPNs and MDS. DNA alterations, or mutations, in blood cells, are the root cause of blood cancer. This causes the blood cells to start acting oddly. These alterations are virtually often connected to external factors. These are lifelong experiences rather than inherited flaws that can be passed down through the generations. Blood cancer treatment in India must be performed by a board-certified hematologist-oncologist and the success rate of…

December 22nd,2023

The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.

The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%. Recently, CAR-T cell therapy targeting B-cell malignancies has encountered a series of inquiries and challenges, particularly concerning discussions on CAR-T cell-related toxicity, resistance, antigen escape, and limitations in persistence. However, Read More

December 21st,2023 CAR-T , Leukemia

If a child unfortunately gets leukemia, should CAR-T Therapy be considered?

In recent years, CAR-T therapy has gained traction in treating leukemia. A quick search yields numerous articles, many of which describe the miraculous effects of CAR-T. Is the efficacy of CAR-T therapy really that impressive? Should CAR-T therapy be considered for a child diagnosed with leukemia? Today, let’s unravel these doubts together! What kind of Read More

December 20th,2023 CAR-T , Leukemia

The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO)

The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO®) IASO Bio and Innovent presented their latest research findings on the Equecabtagene Autoleucel injection (brand name: FUCASO®) for multiple myeloma at the 2023 American Society of Hematology (ASH) Annual Meeting. This study was primarily based on Read More

December 18th,2023 CAR-T

Breakthrough medical research in China brings hope for multiple myeloma patients.

Eque-cel brings new treatment prospects for multiple myeloma. From December 9th to 12th, the Annual American Society of Hematology Meeting (ASH 2023) was held in San Diego, USA. At this conference, the FUMANBA-1 study, led by Professors Chunrui Li from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Lugui Read More

December 15th,2023 CAR-T

Breakthrough in Survival for Late-Stage Cancer Patients with Chinese CAR-T Therapy

Whether it’s multiple treatment failures or recurrent tumors with systemic metastasis, miraculous remissions are still achieved after undergoing treatment! Chinese CAR-T therapy has brought a brand-new hope for various late-stage cancers such as gastric, colorectal, pancreatic, and liver cancers. The renowned CAR-T therapy is almost universally recognized, and its successful development has instilled hope for Read More

December 14th,2023 CAR-T

The world’s first approved fully human BCMA-targeted CAR-T/FUCASO

BCMA CAR-T FUCASO On June 30, 2023，China National Medical Products Administration(NMPA) has approved the New Drug Application (NDA) for FUCASO(Equecabtagene Autoleucel, co-developed and co-commercialized by IASO Bio and Innovent, IASO Bio R&D code: CT103A, Innovent R&Dcode: IBI326) the world’s first fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or Read More

December 13th,2023 CAR-T

Cancer Newsletter: Breakthrough! The Renji Hospital team used CAR-T cells to achieve clinical cure for two patients with advanced liver cancer

Liver cancer is a heavy burden for Chinese people. Data released by the International Agency for Research on Cancer (IARC) last year showed that in China, there are over 410,000 new cases of liver cancer and over 390,000 deaths due to liver cancer each year, accounting for 45.3% and 47.1% of the global total, respectively. Read More

November 22nd,2023 CAR-T

Complete Remission for up to 8 Years! Chinese Innovation in CAR-T Therapy Brings ‘Cure’ Dawn to Late-Stage Cancer Patients!

Two patients with advanced liver cancer, who had multiple treatment failures, relapses, and rapid progression, have achieved complete tumor remission after receiving a new type of immunotherapy! More excitingly, recent follow-ups at a well-known tumor center in Shanghai confirmed that their tumors have been in complete remission for 7 and 8 years, respectively! This means Read More

November 22nd,2023 CAR-T

1
..
11
12
13
14

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.